Dennis Yiannakis

TL;DR: Genes predicted to be involved in known mechanisms drug sensitivity and resistance correlate well with in vitro chemosensitivity and may allow the definition of predictive signatures to guide individualized chemotherapy in lung cancer.

TL;DR: It is reported that BRCA1-depleted cells exhibited increased DNA double strand breaks (DSBs) and decreased clonogenic cell survival upon auranofin treatment, and anti-oxidant agent, N-acetyl cysteine (NAC) protected BRC a1- Depleted cells from DNA damage and apoptosis induced by auran ofin.

TL;DR: This study suggests that auranofin mediates its cytotoxicity via ROS production in ovarian cancer cells which correlates positively with membrane fluidity.

TL;DR: A 48-year-old woman with a positive BRCA1 gene mutation was diagnosed with stage 3b high-grade ovarian endometrioid carcinoma and treated with adjuvant carboplatin at a dose of 740 mg (AUC 6) in 3-weekly cycles and developed left optic disc atrophy with 6/18 visual acuity, while the right eye remains asymptomatic.

TL;DR: A 52-year-old woman large cell neuroendocrine carcinoma patient with progressive stage IV disease in the chest, liver, adrenal glands and, particularly, the brain, who achieved a marked response to a fourth-line combination of docetaxel, cisplatin and temozolomide is reported.